v3.26.1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Product Reserve Accounts
The following table summarizes the balances and activity in each of the product reserve accounts for the three months ended March 31, 2026.
(in thousands)Rebates and DiscountsCo-Pay AssistanceProduct ReturnsTotal
Beginning balance at December 31, 2025$418 $30 $10 $458 
Provision related to revenue associated with sales processed in the three month period ended March 31, 2026238 40 3 281 
Adjustments related to revenue associated with sales processed in prior periods— — — — 
Credits and payments made during the period(176)(52)— (228)
Balance as of March 31, 2026$480 $18 $13 $511 
Schedule of Accounts, Notes, Loans and Financing Receivable
The following table provides a rollforward of accounts receivable for the three months ended March 31, 2026.

(in thousands)Accounts Receivable
Beginning balance at December 31, 2025$573 
Increase in accounts receivable for drug product sales2,852 
Decrease in accounts receivable for cash collections(2,312)
Balance as of March 31, 2026$1,113 
Schedule of Allocation of Performance Obligation
The following table summarizes the allocation of transaction price to the performance obligations under the Norgine Agreement based on the weighting of estimated stand-alone selling price for these performance obligations at the inception of the agreement.

Allocation of Transaction PriceRevenue Recognized
(in thousands)Three Months Ended March 31,
Performance Obligation:20262025
License$27,639 $— $27,639 
Research and development services: WHIM312 — 17 
Research and development services: CN 1,724 58209 
Drug product supply181 181 — 
Total$29,856 $239 $27,865 
Rollforward of Deferred Revenue
The following table provides a rollforward of deferred revenue three months ended March 31, 2026.

(in thousands)Deferred Revenue
Beginning balance at December 31, 2025$1,085 
Decrease in deferred revenue for revenue recognized(58)
Balance as of March 31, 2026$1,027